| Title: |
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer ; Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01 |
| Authors: |
Pant, Shubham; Fan, Jia; Oh, Do-Youn; Choi, Hye Jin; Kim, Jin Won; Chang, Heung-Moon; Bao, Lequn; Sun, Hui-Chuan; Macarulla, Teresa; Xie, Feng; Metges, Jean-Phillippe; Ying, Jie'er; Bridgewater, John; Lee, Myung-Ah; Tejani, Mohamedtaki A.; Chen, Emerson Y.; Wasan, Harpreet; Ducreux, Michel; Bao, Yuanyuan; Wu, Xiaotian; Zhao, Yi; Garfin, Phillip M.; Gable, Jonathon; Harding, James J. |
| Contributors: |
Oh, Do-Youn |
| Publisher Information: |
American Medical Association |
| Publication Year: |
2026 |
| Collection: |
Seoul National University: S-Space |
| Description: |
This follow-up analysis of the phase 2 HERIZON-BTC-01 trial evaluates the efficacy, patient-reported outcomes, and safety profile of zanidatamab in patients with ERBB2-amplified biliary tract cancer with an HER2 immunohistochemistry score of 3+ or 2+ after 33 months of follow-up. ; Y ; 1 |
| Document Type: |
article in journal/newspaper; manuscript |
| Language: |
unknown |
| Relation: |
https://hdl.handle.net/10371/231076; 001627141300001; 250443 |
| DOI: |
10.1001/jamaoncol.2025.4736 |
| Availability: |
https://hdl.handle.net/10371/231076; https://doi.org/10.1001/jamaoncol.2025.4736 |
| Accession Number: |
edsbas.9623D41C |
| Database: |
BASE |